BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34848480)

  • 1. Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01).
    Matsuhashi N; Takahashi T; Tanaka C; Yawata K; Yamada M; Iwata Y; Kiyama S; Mizutani C; Tajima JY; Ishihara T; Yoshida K
    Anticancer Res; 2021 Dec; 41(12):6247-6257. PubMed ID: 34848480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
    Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
    Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan.
    Chao JY; Wang HM; Chiang FF; Lin JC; Chang CF; Lin JF; Yeh HL
    J Chin Med Assoc; 2014 Mar; 77(3):128-32. PubMed ID: 24398439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
    Yang B; Shan J; Feng Y; Dai N; Li M; Chen C; He S; Wang G; Xiao H; Li C; Wang D
    Radiat Oncol; 2020 May; 15(1):94. PubMed ID: 32375814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial).
    Matsusaka S; Ishihara S; Kondo K; Horie H; Uehara K; Oguchi M; Murofushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Nakajima T; Watanabe T
    Radiother Oncol; 2015 Aug; 116(2):209-13. PubMed ID: 26337743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
    Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
    World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer.
    Beppu N; Yoshie H; Kimura F; Aihara T; Doi H; Kamikonya N; Matsubara N; Tomita N; Yanagi H; Yamanaka N
    Surg Today; 2016 Oct; 46(10):1123-31. PubMed ID: 26704191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
    Ishihara S; Matsusaka S; Kondo K; Horie H; Uehara K; Oguchi M; Murofushi K; Ueno M; Mizunuma N; Shinbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Nakajima T; Watanabe T
    Radiat Oncol; 2015 Jan; 10():24. PubMed ID: 25612635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of neoadjuvant preoperative chemotherapy with S-1, oxaliplatin, and bevacizumab plus radiation in patients with locally advanced rectal cancer.
    Sato H; Shimada M; Kurita N; Iwata T; Yoshikawa K; Higashigima J; Chikakio M; Kashihara H; Takasu C; Matsumoto N; Eto S
    Int J Clin Oncol; 2015 Jun; 20(3):543-8. PubMed ID: 25080061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer.
    Lee EM; Hong YS; Kim KP; Lee JL; Kim SY; Park YS; Choi DH; Kim JH; Lim SB; Yu CS; Kim JC; Lee JH; Kim AY; Kim TW
    Cancer Sci; 2013 Jan; 104(1):111-5. PubMed ID: 23057495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
    Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R;
    Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer.
    Yang XH; Li KG; Wei JB; Wu CH; Liang SX; Mo XW; Chen JS; Tang WZ; Qu S
    Sci Rep; 2020 Jul; 10(1):12539. PubMed ID: 32719436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
    Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
    Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer.
    Imano N; Murakami Y; Kubo K; Kawahara D; Takeuchi Y; Nishibuchi I; Kimura T; Kochi M; Takakura Y; Shimizu W; Egi H; Uegami S; Ohge H; Takahashi S; Ohdan H; Nagata Y
    J Radiat Res; 2021 Mar; 62(2):300-308. PubMed ID: 33341902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
    Vestermark LW; Jensen HA; Pfeiffer P
    Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
    Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.